Publications

  • Search by Title

  • Search by Date

  • Select a Category

  • Reset
Eblasakimab, Translational work | June 23, 2023

Targeting type 2 immune activation beyond atopic dermatitis

Donald Y.M. Leung, Paola Facheris, Karen A. Veverka, Ferda Cevikbas, Emma Guttman-Yassky
Leung et al- Review in AAAAI - June 2023
Clinical publications, Eblasakimab | June 19, 2023

Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers

Ferda Cevikbas, Alison Ward, Carl Firth, Karen Veverka
Clinical Immunology (2023), Volume 253, 109677
Farudodstat, Translational work | May 18, 2023

A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment

Thomas Rouille, Silvia Barbosa, Ana Steinhoff, Ilaria Piccini, Janin Edelkamp, Ferda Cevikbas, Marta Bertolini
Abstract number LB1777
Eblasakimab, Translational work | May 17, 2023

Neuromodulation Beyond Itch is Blocked by Targeting IL‐13Rα1 with Eblasakimab

Yannick Miron, Paul Miller, Carl Firth and Ferda Cevikba
Abstract number 1594
Eblasakimab, Translational work | May 17, 2023

Downstream effects of IL-13Rα1 blockade on Type 2 inflammation and Th1 immune axis activation in atopic dermatitis

Sriya V. Reddy, Zachary Bordeaux, Ahmad Rajeh, Darshan Sivaloganathan, Hannah Cornman, Anusha Kambala, Jackson Adams, Ferda Cevikbas, Shawn G. Kwatra, Madan M. Kwatra
Abstract number LB1751
Clinical publications, Eblasakimab | May 17, 2023

Eblasakimab monotherapy improves moderate-to-severe atopic dermatitis symptoms across anatomical regions in a Phase 1 study

Karen A. Veverka, Josemund Menezes, Steven Tien Guan Thng
Abstract number 657
Eblasakimab, Translational work | April 18, 2023

Spatial localization and functional role of IL-13Rα1 signalling in atopic dermatitis

Zachary A. Bordeaux, Ahmed Rajeh, Jackson Adams, Ferda Cevikbas, Shawn G. Kwatra, Madan M. Kwatra, Ph.D
51st Annual European Society for Dermatological Research (ESDR) Meeting, September – October 2022
Eblasakimab, Translational work | April 18, 2023

Insight into novel itch pathways and spontaneous neuronal activity by targeting interleukin 13 receptor alpha 1 (IL13Rα1) with eblasakimab

Yannick Miron, Paul Miller, Carl Firth and Ferda Cevikbas
51st Annual European Society for Dermatological Research (ESDR) Meeting, September – October 2022
Clinical publications, Eblasakimab | April 18, 2023

Eblasakimab, a monoclonal antibody targeting IL-13Ra1, reduces serum biomarkers that are associated with atopy and correlated with disease severity, in patients with moderate-to-severe atopic dermatitis

Ferda Cevikbas, Jacob P. Thyssen, Eric Simpson, Alison Ward, Steven Tien Guan Thng, Karen A. Veverka
Poster number 0243
Clinical publications, Eblasakimab | April 18, 2023

Eblasakimab improves itch and sleep loss in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study

Karen A. Veverka, Josemund Menezes, Steven Tien Guan Thng, Eric Simpson
Poster number 0342
Clinical publications, Eblasakimab | April 18, 2023

Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study

Karen A. Veverka, Josemund Menezes, Steven Tien Guan Thng, Melinda Gooderham, Eric Simpson
Poster number 0343
Eblasakimab, Translational work | April 18, 2023

New insights into neuronal itch mechanisms by targeting IL-13Rα1 with eblasakimab

Yannick Miron, Paul Miller, Carl Firth, and Ferda Cevikbas
Abstract number LB1039